Clinical study of modified immune cells (NRC-NK) for the treatment of stage ? colorectal cancer
Ontology highlight
ABSTRACT: Interventions: Patient1:Received 1 x 10^7 / m^2 NRC-NK cells infusion on day 0, followed by a second 6 x 10^7 / m^2 NRC-NK cells infusion on day 7 and a third 3 x 10^8 / m^2 NRC -NK cells infusion on day 14;Patient1:6 x10^7/m2 NRC-NK cells,twice a week and 3 x10^8/m2 NRC-NK cells, twice a week, with one week between the two doses;Patient2:Accept 3 x 10 ^ 8 / m ^ 2 CAR-NK cell input twice a week for 3 weeks;Patient3:Accept 3 x 10 ^ 8 / m ^ 2 CAR-NK cell input twice a week for 3 weeks
Primary outcome(s): blood routine;Urine routine;Liver and kidney function;Electrocardiogram;weight;Physical status score;Ultra sound examination of ascites;CT;MRI;Survival period;Ultra sound examination of liver and gallbladder;Circulating tumor cells;Analysis of serum CEA levels;Blood cell phenotype analysis;Plasma cytokine detection;Ascites cell phenotype analysis;Ascites cytokine detection
Study Design: Dose comparison
DISEASE(S): Colorectal Cancer
PROVIDER: 2662953 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA